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1. Introduction
   Hepatitis B virus (HBV) is a double-stranded DNA 
virus that belongs to the family of hepadnaviruses. 
Other members of the family include Peaking duck 
hepatitis virus, woodchuck hepatitis virus and ground 
squirrel hepatitis virus[1]. Blumberg and colleagues 
identified HBsAg in Philadelphia in 1965 in the blood 
of an Australian aborigine, the reason why HBsAg was 
initially named Australia antigen[2]. Blumberg received 
Noble Prize in Medicine in 1977 for this ground 
breaking discovery.
  HBV infects nearly 350 million people worldwide. The 
clinical manifestations vary widely with asymptomatic 
acute viral B hepatitis on one end and hepatocellular 
carcinoma (HCC) on the other end of the spectrum. 
There are about 400 million HBV careers worldwide. 
Of them 75%-80% reside in Asia and Western Pacific. 
HBV is responsible for over 1 million deaths per year 
globally. It is a major cause of cirrhosis of liver and 
HCC worldwide[1].
  HBV is mainly transmitted by percutaneous and 
membrane exposure to infected body fluids. HBsAg and 
HBV DNA by PCR have been identified in most body 
secretions e.g. blood, saliva, menstrual and vaginal 
discharges, seminal fluid and serous discharges with 
the exception of stool[1].  HBV replicates in hepatocytes, 
but HBV encoded proteins have been identified in other 
body tissues like testes, stomach, colon, kidney, bone 
marrow, peripheral mononuclear cells, nerve ganglia 
and skin, which represent large extra-hepatic reservoir 
of HBV[3].
  HBV is transmitted from infected mother to neonate 
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in or around the time of birth. 60%-90% babies born to 
HBeAg positive mothers and 15%-20% born to HBeAg 
negative mothers become infected respectively. There is 
also risk of transmission of HBV if the pregnant mother 
has acute viral B hepatitis in second or third trimester 
or within two months of labour. HBV has been detected 
in breast milk, but it is probably not transmitted through 
breast milk[3].
  HBV is one of the commonest causes of post-
transfusion hepatitis. Intravenous drug abuse is also 
an important mode of transmission of HBV. A single 
needle stick injury from a patient positive for HBeAg 
is associated with 30% risk of acquiring the infection. 
Sexual transmission of HBV is another important route 
of spread of the virus[1]. Dentists and barbers are likely 
sources of some HBV infections. Tattooing, acupuncture, 
body piercing, artificial insemination and organ 
transplantation etc. are also less frequent sources of 
HBV infection[3].
  In intermediate prevalence countries like Bangladesh, 
lifetime risk of acquiring HBV infection is above 
40% and transmission of HBV is both vertical and 
horizontal. In Europe and in North America, sexual 
route is the main route of transmission of HBV. It occurs 
in individuals predominantly below 50 years of age. 
Needle sharing among intra-venous drug abusers and 
occupational exposure to contaminated blood and blood 
products also remain important routes of spread for the 
virus[3].
  The precore/core region of the HBV genome encodes 
the nucleocapsid protein (HBcAg) and HBeAg[4,5]. 
The core open reading frame has two transcripts with 
heterogeneous 5’ ends and two in-phase initiation 
codons. HBeAg is translated from the precore mRNA 
producing a precursor polypeptide comprising the 
precore and the entire core region. The precore 
polypeptide is translocated into the endoplasmic 
reticulum by a signal peptide. Cleavage of the amino 
and carboxy termini results in a secretory protein 
HBeAg. HBcAg is translated from the pregenomic RNA. 
  The biological role of HBeAg in the HBV replication 
cycle is uncertain. Expression of HBeAg is nonessential 
for virus replication in animal models[6] and in 
humans[7]. It has been suggested that HBeAg may act 
as a tolerogen or a target for immune response. In 
utero exposure to HBeAg can induce immune tolerance 
in newborn mice[8]. Perinatal transmission of HBV 
from HBeAg-positive mothers results in chronic HBV 
infection in the majority of babies[9]. In addition, HBeAg 
appears to modulate the host’s immune response[10-
13]. Precore variants that do not produce HBeAg may be 
selected because they can evade immune clearance.
  Mutations in the precore region of the HBV genome 
have been described[14-16]. It results in HBeAg negative 
HBV infection. The predominant mutation involves 
a G to A change at nucleotide 1 896 (G1896A). This 
results in a premature stop codon (eW28X) and prevents 
translation of the precore protein. Thus the production 
of HBeAg is completely abolished[17].
  Core promoter region (nucleotides 1 742 to 1 849) is 
located upstream of the precore region (nucleotides 1 
814 to 1 901). It has important role in HBV replication as 
well as HBeAg production[18]. Mutations in these regions 
downregulate precore mRNA transcription and HBeAg 
synthesis[19,20]. The most common core promoter variant 
results in substitution in A to T at nucleotide 1 762 
and G to A at nucleotide 1 764 (A1762T, G1764A)[21-23]. 
These changes commonly leads to HBeAg negative HBV 
infection[21].
2. Material and methods
  Patients with chronic HBV infection (HBsAg positive 
for at least 6 months) attending our OPDs in Dhaka, 
Bangladesh between April 2010 and April 2012 were 
studied prospectively. Written informed consent was 
obtained from each patient. The patients had to be 
negative for anti-HCV antibody and positive for serum 
HBV DNA (>1×105 copies/mL) using a DNA hybridization 
assay (Digene Hydrid Capture2 system; Digene 
Corporation, Gaithersburg, Maryland, USA); they were 
enrolled irrespective of their HBeAg status and liver 
enzyme levels. Patients with clinical evidence of liver 
cirrhosis were excluded.
  All patients underwent percutaneous liver biopsy. 
Biopsies were done using trucut biopsy needle under 
local anaesthesia. Patient characteristics are shown in 
Table 1. We checked prothrombin time, platelet count, 
bleeding time and clotting time in every patient within a 
week before the procedure. Liver biopsies were done if 
baseline prothrombin time was not prolonged more than 
3 s beyond control value, platelet count was not less 
than 100 000/mm3 and bleeding and clotting times were 
within normal limits. None of the patients experienced 
any complication except for the occasional complaint of 
mild right upper abdominal or right shoulder tip pain 
in few cases. The patients were followed up at 15 min 
intervals for 1 h and then at 30 min intervals for another 
2 h. Bed rest was given for 24 h and patients were 
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discharged 48 hours post-liver biopsy. Biopsies were 
scored using Knodell score and histologic activity index 
(HAI) score. 
Table 1
Characteristics of study population.
Parameter Value
Total patients 155
Age (years) 25 (8-55)
Gender (Male: Female)  119:36
Wild type 102




  A total of 155 patients were studied. Results in HBeAg 
positive wild type CHB show that HAI score (i.e. necro-
inflammatory score) was between 1-3 in 39/102 patients, 
between 4-8 in 44/102 patients, between 9-12 in 18/102 
patients and 1/102 patients had score between 13-
18. In HBeAg negative pre-core/core promoter mutant 
CHB, these figures are 26/53, 16/53, 8/53 and 3/53, 
respectively.
  38.2% wild type CHB patients included in this study 
had minimal chronic hepatitis, 43.1% had mild chronic 
hepatitis and 17.6% had moderate chronic hepatitis 
while severe chronic hepatitis was present in 0.9% 
patients. In pre-core/core promoter mutant CHB 
patients, these figures were 49%, 30.2%, 15.1% and 5.6%, 
respectively.
  Fibrosis score was <2 and >2 in 82/102 and 20/102 
patients with wild type CHB and in pre-core/core 
promoter mutant CHB, it was <2 and >2 in 38/53 and 
15/53 patients respectively.
  80.4% patients with wild type CHB had fibrosis score 
<2 and 19.6% had >2. In case of pre-core/core promoter 
mutant CHB, it was 71.7% and 28.3% respectively. 
4. Discussion
  Our study reveals that CHB patients infected with core/
core promoter mutant HBV tend to develop more severe 
necro-inflammation and fibrosis in the liver compared 
to those who are infected with wild type HBV. 
  In 2004, an Indian study involving 60 patients 
conducted by a group from G.B. Pant Hospital, New 
Delhi demonstrated statistically significant difference in 
liver fibrosis between wild type and core/core promoter 
mutant CBH patients, with fibrosis score being higher 
in core/core promoter mutant CHB. Although these 
patients also had higher HAI score than those infected 
with wild type HBV, the difference was not statistically 
significant[24].
  A Korean study in 2004 also yielded similar results. 
The study included chronic HBV infected 85 young, 
male patients and demonstrated lower fibrosis score 
in those wild type HBV infection than those with core/
core promoter mutant HBV infection. Here also the 
correlation was not significant statistically in case of 
HAI score[25].  
  A Turkish study in 2003, that included 354 CHB 
patients revealed significant difference between necro-
inflammatory activity and precore/core promoter mutant 
and wild type CHB. However the difference in fibrosis 
was not significant[26].
  In one of our previous works where we recruited 80 
CHB patients, it was seen that 7.69% patients with wild 
type CHB had minimal chronic hepatitis, 69.23% had 
mild chronic hepatitis, 19.23% had moderate chronic 
hepatitis 3.85% had severe chronic hepatitis. In case 
of pre-core/core promoter mutant CHB these figures 
were 10.71%, 53.57%, 25% and 10.71%, respectively. Our 
study showed that patients with pre-core/core promoter 
mutant CHB tend to develop moderate to severe chronic 
hepatitis more[27].
  In conclusion our study shows that core/core promoter 
mutant HBV infection leads to more marked necro-
inflammation and fibrosis in the liver compared 
wild type HBV infection. Out finding is more or less 
consistent with similar studies carried our elsewhere as 
well as in Bangladesh. This may well explain disease 
progression and lack of response to anti-viral treatment 
in HBeAg negative CHB patients.
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